%0 Journal Article
%T First-line Combination Immunotherapy in Advanced Non-small Cell Lung Cancer
%A Xiaoxiao PENG
%A Qing ZHOU
%J Öйú·Î°©ÔÓÖ¾
%D 2018
%R : 10.3779/j.issn.1009-3419.2018.12.11
%X Programmed death 1/programmed death ligand 1 (PD-1/PD-L1) inhibitor has become one of the important treatment options for patients with advanced non-small cell lung cancer (NSCLC). However, only a small subset of patients with NSCLC can currently receive single-agent PD-1 inhibitors as first-line therapy, for the limitations of population selection exclude most patients from immuno-oncology (IO) monotherapy. In order to expand the candidate population for IO first-line treatment and make more newly diagnosed patients benefit from IO treatment, a series of studies are focusing on the combination of IO and other drugs in NSCLC. We reviewed the latest clinical data of IO first-line combination therapy in recent years, suggesting that on the basis of PD-1/PD-L1 inhibitors, combined with other IO, chemotherapy, anti-angiogenic drugs, targeted therapy or radiotherapy may produce synergistic anti-tumor effects. It is expected to benefit more newly diagnosed patients.£¿
%K Programmed death-1/programmed death-ligand-1 inhibitors
%K Lung neoplasms
%K First-line combination
%K Immuno-oncology
%U http://www.lungca.org/index.php?journal=01&page=article&op=view&path%5B%5D=10.3779%2Fj.issn.1009-3419.2018.12.11